Ciclosporin A therapy is associated with disturbances in glucose metabolism in dogs with atopic dermatitis.
The effect of ciclosporin A (CsA) on glucose homeostasis was investigated in 16 dogs with atopic dermatitis by determining plasma glucose, serum fructosamine and insulin concentrations, and serial insulin and glucose concentrations following a glucagon stimulation test, before and 6 weeks after CsA therapy at 5 mg/kg once daily. All dogs completed the study. Following CsA treatment, the median serum fructosamine concentrations were significantly higher (pretreatment 227.5 μmol/L; post-treatment 246.5 μmol/L; P = 0.001; reference range 162-310 μmol/L). Based on analyses of the areas under concentration-time curves (AUC) pre- and post-CsA treatment, plasma glucose concentrations were significantly higher (AUC without baseline correction 31.0 mmol/L/min greater; P = 0.021) and serum insulin concentrations were significantly lower (AUC without baseline correction 217.1 μIU/mL/min lower; P = 0.044) following CsA treatment. Peak glucose concentrations after glucagon stimulation test were significantly higher following CsA treatment (10.75 versus 12.05 mmol/L; P = 0.021), but there was no significant difference in peak serum insulin (52.0 versus 35.0 μIU/mL; P = 0.052). There was a negative correlation between baseline uncorrected insulin AUC and trough serum log CsA concentrations (r = -0.70, P = 0.005). The administration of CsA to dogs with atopic dermatitis leads to disturbances in glucose homeostasis. The clinical significance of this is unclear, but it should be taken into account when considering CsA treatment in dogs that already have such impairments.
Division of Veterinary Clinical Sciences, The Roslin Institute and Royal (Dick) School of Veterinary Studies, Easter Bush Veterinary Centre, The University of Edinburgh, Hospital for Small Animals, Roslin, Midlothian EH25 9RG, UK.
Marcel
M
Kovalik
Keith L
KL
Thoday
Ian G
IG
Handel
Barend M de C
BM
Bronsvoort
Helen
H
Evans
Adri H M
AH
van den Broek
Richard J
RJ
Mellanby
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000662:veterinary*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004334:Drug Administration Schedule / Q000662:veterinary; D005260:Female; D019270:Fructosamine / Q000097:blood; D005934:Glucagon / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D007328:Insulin / Q000097:blood; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
D001786:Blood Glucose; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D007328:Insulin; D019270:Fructosamine; D016572:Cyclosporine; D005934:Glucagon